MarketCap
Facebook
X
Telegram
Gritstone Oncology Balance Sheet 2023-2011 | GRTS
Brief overview of Gritstone Oncology's balance sheet strength
The balance sheet is assessed across five available annual reports spanning 2019 to 2023.
The size of the balance sheet remained broadly stable, moving from $184.4 million to $177.8 million. There was no meaningful expansion.
Asset growth of -3.6% came with a +151.6% rise in liabilities. Financial leverage became more prominent.
Equity represents 29.2% of assets versus 72.9% initially. The capital structure appears balanced.
The period ended with net cash: net debt stood at -$15.9 million. This supports financial flexibility.
Cash accounts for 35.4% of assets versus 31.1% initially. The change indicates the degree of financial flexibility.
Retained earnings remain negative at -$659.6 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Balance sheet takeaway
Gritstone Oncology's balance sheet presents a mixed picture: strengths coexist with a limited cushion. Future capital and debt trends are particularly important.
Annual Balance Sheet Gritstone Oncology
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-15.9 M | -30.9 M | -66.9 M | -145 M | -33.9 M | -41.7 M | -28.5 M | -12.4 M | - | - | - | - | - |
Long Term Debt |
40.1 M | 19.3 M | 18.9 M | 19.2 M | - | 10.5 M | - | - | - | - | - | - | - |
Long Term Debt Current |
6.9 M | 5.29 M | 7.48 M | 5.87 M | 2.5 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 30.5 M | 25.3 M | 12.4 M | 2.24 M | - | - | - | - | - |
Total Current Liabilities |
27.3 M | 34.8 M | 40 M | 27 M | 19.5 M | 15.1 M | 7.65 M | - | - | - | - | - | - |
Total Liabilities |
126 M | 70 M | 62 M | 54.8 M | 50 M | 40.4 M | 20 M | 4.73 M | - | - | - | - | - |
Deferred Revenue |
2.35 M | 5.13 M | 17.2 M | 3.48 M | 4.96 M | 5.34 M | - | - | - | - | - | - | - |
Retained Earnings |
-660 M | -521 M | -401 M | -326 M | -221 M | -126 M | -61.6 M | -20.2 M | - | - | - | - | - |
Total Assets |
178 M | 241 M | 278 M | 222 M | 184 M | 190 M | 117 M | 46.4 M | - | - | - | - | - |
Cash and Cash Equivalents |
63 M | 55.5 M | 93.3 M | 170 M | 57.4 M | 52.2 M | 39 M | 12.4 M | - | - | - | - | - |
Book Value |
51.8 M | 171 M | 216 M | 167 M | 134 M | 149 M | 97.3 M | 41.7 M | - | - | - | - | - |
Total Shareholders Equity |
51.8 M | 171 M | 216 M | 167 M | 134 M | 149 M | 97.3 M | 41.7 M | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Gritstone Oncology
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
40.5 M | 40.3 M | 40.1 M | 29.9 M | 29.7 M | 29.6 M | 19.3 M | 19.3 M | 17.8 M | 18.7 M | 18.9 M | 19.8 M | 16.2 M | 17.6 M | 19.2 M | 20.8 M | 22.3 M | 20.1 M | - | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
120 M | 123 M | 126 M | 113 M | 113 M | 69.1 M | 70 M | 68.4 M | 50.6 M | 54.3 M | 62 M | 63.3 M | 45.4 M | 47.6 M | 54.8 M | 50.5 M | 49.4 M | 47.6 M | 50 M | 52.3 M | 45.8 M | 43.3 M | 40.4 M | 40.5 M | 40.4 M | 40.4 M | 20 M | 20 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
698 K | 1.28 M | 2.35 M | 1.3 M | 2.82 M | 2.8 M | 5.13 M | 8.69 M | 11.1 M | 12.3 M | 17.2 M | 13.8 M | 2.94 M | 3.39 M | 3.48 M | 5.53 M | 5.78 M | 4.51 M | 4.96 M | 5.4 M | 5.5 M | 5.42 M | 5.34 M | 5.21 M | 5.34 M | 5.34 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-723 M | -700 M | -660 M | -629 M | -590 M | -555 M | -521 M | -490 M | -460 M | -430 M | -401 M | -372 M | -343 M | -318 M | -326 M | -299 M | -273 M | -247 M | -221 M | -193 M | -166 M | -145 M | -126 M | -109 M | -126 M | -126 M | -61.6 M | -61.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
143 M | 137 M | 178 M | 187 M | 223 M | 210 M | 241 M | 205 M | 214 M | 243 M | 278 M | 271 M | 224 M | 247 M | 222 M | 123 M | 146 M | 163 M | 184 M | 209 M | 228 M | 175 M | 190 M | 113 M | 190 M | 190 M | 117 M | 117 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
50.9 M | 42.4 M | 63 M | 29.5 M | 41.4 M | 47.1 M | 55.5 M | 64.9 M | 65.7 M | 69.2 M | 93.3 M | 131 M | 64.1 M | 109 M | 170 M | 57.6 M | 62.6 M | 54.9 M | 57.4 M | 117 M | 108 M | 34.6 M | 52.2 M | 65.9 M | 52.2 M | 52.2 M | 39 M | 39 M | - | - | 12.4 M | - | - | - | 23.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
22.2 M | 14 M | 51.8 M | 74 M | 110 M | 141 M | 171 M | 137 M | 163 M | 189 M | 216 M | 208 M | 179 M | 199 M | 167 M | 72 M | 96.2 M | 115 M | 134 M | 156 M | 182 M | 132 M | 149 M | 72.7 M | 149 M | 149 M | 97.3 M | 97.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
22.2 M | 14 M | 51.8 M | 74 M | 110 M | 141 M | 171 M | 137 M | 163 M | 189 M | 216 M | 208 M | 179 M | 199 M | 167 M | 72 M | 96.2 M | 115 M | 134 M | 156 M | 182 M | 132 M | 149 M | 72.7 M | 149 M | 149 M | 97.3 M | 97.3 M | - | - | 41.7 M | - | - | - | 24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Gritstone Oncology, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
